NOUVASANT PHARMhealth LTD.[Jiangsu,China] Business Type: Manufacturer , Trade Company , Agent , Distributor/WholesalerMain Mark: Africa , Americas , Asia , Caribbean , East Europe , Europe , Middle East , North Europe , Oceania , Other Markets , West Europe , WorldwideExporter: 71% - 80%Certs: FDADescription: Cotrimoxazole Oral Suspension,Cotrimoxazole Oral Suspension 240mg 5ml 100ml,Cotrimoxazole
Oral Suspension: 200 Mg Sulfamethoxazole And 40 Mg Trimethoprim
Co-Trimoxazole Paediatric Suspension is indicated for the treatment of the following infections when owing to sensitive organisms:
Treatment and prevention of Pneumocystis jiroveci (P. carinii) pneumonitis
Treatment and prophylaxis of toxoplasmosis
Treatment of nocardiosis
The following infections may be treated with Co-Trimoxazolewhere there is bacterial evidence of sensitivity to Co-Trimoxazole and good reason to prefer the combination of antibiotics in Co-Trimoxazole to a single antibiotic:
Acute uncomplicated urinary tract infection
Acute otitis media
Acute exacerbation of chronic bronchitis
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
If you are a distributor, please inquirewith us about product registration, importing and/or marketing our products inyour country or region.
If you are a consumer, don't hesitate tocontact us about more information for this product.